Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00368277
Status:
COMPLETED
Last Update Posted:
2011-03-25
First Post:
2006-08-22
Brief Title:
A Safety and Efficacy Trial of Aliskiren 150mg 300 mg Compared to Ramipril 5mg 10mg in the Elderly
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A 36 Week Randomized Double-blind Parallel Group Multi-center Active-controlled Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients 65 Years Old With Systolic Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None